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a  b  s  t  r  a  c  t
Background:  It has  been  reported  that inﬂammation  is associated  with  long-term  maintenance  of  sinus
rhythm  after  electrical  cardioversion  for non-valvular  atrial  ﬁbrillation  (AF).  However,  the relation
between  high-sensitive  C-reactive  protein  (hs-CRP)  and  the  recurrence  of AF  after  medical  cardiover-
sion  is  unknown.  On  the other  hand,  bepridil  is very  effective  in  restoring  sinus  rhythm  for  patients  with
refractory  AF.
Methods and  results:  In 119  patients  with  non-valvular  AF lasting  >6  months  who  failed to  maintain  sinus
rhythm  after  medical  cardioversion  without  bepridil  or electrical  cardioversion,  we prescribed  bepridil.
We  divided  our  patients  into  success  group  who  maintained  sinus  rhythm  for at  least  6 months  using
bepridil  and  failure  group,  and compared  the following  parameters,  which  were  measured  just  before
prescription  of  bepridil,  between  the  two  groups:  hs-CRP  as  a marker  of  inﬂammation,  left ventricular
end-diastolic  dimension,  ejection  fraction,  and  left  atrial  dimension  as echocardiographic  markers,  and
the  incidence  of  dyslipidemia,  hypertension,  and diabetes  mellitus.  After  the  treatment  with  bepridil,  57
patients  converted  to sinus  rhythm;  however,  12 patients  among  these  57  patients  could  not  maintain
sinus  rhythm.  Therefore,  the  success  group  consisted  of  45 patients  (38%).  Univariate  analysis  revealed
that  left atrial  dimension  and  the  value  of hs-CRP  were  signiﬁcantly  lower  and  ejection  fraction  was
signiﬁcantly  higher  in  the  success  group  than the  failure  group.  Multivariate  analysis  showed  that  hs-CRP
and  left  atrial  dimension  were  independent  factors  for  AF recurrence.
Conclusions: Bepridil  is  effective  in  restoring  sinus  rhythm  for refractory  AF  patients.  Inﬂammation,  in
addition  to left  atrial dimension,  may  be  associated  with  successful  cardioversion  using  bepridil.
3  Jap© 201
ntroduction
Some evidence has shown that inﬂammation, especially high-
ensitive C-reactive protein (hs-CRP), is correlated with the
resence of non-valvular atrial ﬁbrillation (AF) [1,2]. Moreover,
t has been reported that hs-CRP levels may  identify the patients
ith a higher risk of unsuccessful cardioversion [3], as well as
atients with AF recurrence [4,5]. Bepridil is one of the most pow-
rful agents that can reverse AF and restore sinus rhythm [6–9].
ur previous report has shown that bepridil can maintain sinus
hythm in approximately 60% of patients with persistent AF after
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failed electrical cardioversion [9]. Therefore, in this study, we inves-
tigated whether inﬂammation, especially the hs-CRP levels, can be




Between June 2006 and January 2010, we prescribed bepridil
for the purpose of cardioversion in patients with non-valvular AF
lasting >6 months who failed to maintain sinus rhythm after medi-
cal cardioversion without bepridil or electrical cardioversion and
who refused ablation therapy for AF. In this study, we  deﬁned
refractory AF as patients who could not maintain sinus rhythm
after medical cardioversion using at least two antiarrhythmic
agents excluding bepridil. The duration of AF was determined by
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lectrocardiogram and from the patients’ declarations. We
xcluded patients with inﬂammatory or neoplastic diseases, coro-
ary artery disease, valvular AF, congestive heart failure, or left
entricular dysfunction (ejection fraction <45%), and patients
reated long term with corticosteroids or who had an implanted
acing device. All patients underwent echocardiography, 24-h
olter electrocardiography, and blood examination just before the
rescription of bepridil. Anticoagulation therapy using warfarin
as performed according to the current guidelines [10]. Before the
rescription of bepridil, we tried to prescribe at least two  antiar-
hythmic agents including pilsicainide, propafenone, cibenzoline,
r disopyramide. If the patients failed to recover to sinus rhythm
hrough medical cardioversion without bepridil, we  recommended
lectrical cardioversion. If they agreed to receive the electrical
ardioversion, they underwent transesophageal echocardiography
o check for a thrombus in the left atrium after admission [11].
he protocol of electrical cardioversion was as follows: a shock
as delivered with external paddles positioned in the anterior-
pex position connected to an external electrical cardioverter for
iphasic external cardioversion. The ﬁrst shock energy was deliv-
red at 200 J. If the ﬁrst shock attempt failed to convert to sinus
hythm, the second shock was delivered at 300 J. The next shock
as delivered at 360 J. If cardioversion was unsuccessful at 360 J,
ntravenous antiarrhythmic agents, either pilsicainide or disopy-
amide, were added and a ﬁnal cardioversion was  attempted at
60 J. If the patients failed to recover to sinus rhythm after electri-
al cardioversion, we prescribed bepridil to be administered after
ischarge in the out-patient clinic. If the patients refused to receive
lectrical cardioversion, we prescribed bepridil without electrical
ardioversion.
dministration of bepridil
In  the study patients, bepridil was prescribed according to the
ollowing protocol [9]. Bepridil was given at an initial dose of
00 mg/day for 3 months, with titration to 150–200 mg/day if the
ow dose failed to restore sinus rhythm. Bepridil was continued
or at least 12 months even if sinus rhythm was  not recovered.
epridil was discontinued if severe side effects including torsades
e pointes occurred.
arameters correlated with successful medical cardioversion
sing bepridil
Just  before the administration of bepridil, a blood sample was
rawn, and echocardiography was performed. Citrated plasma was
tored at −70 ◦C until analysis. An immunonephelometry assay
Sekisui Medical Co. Ltd., Tokyo, Japan) was used to measure
s-CRP. Other serum markers including serum low-density lipopro-
ein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol,
riglyceride, fasting glucose, hemoglobin A1c, and creatinine were
lso measured.
On  echocardiography before the administration of bepridil,
e evaluated the left ventricular end-diastolic dimension, left
entricular ejection fraction, and left atrial dimension. We  also
valuated the traditional coronary risk factors including dysli-
idemia, hypertension, and diabetes mellitus. Dyslipidemia was
dentiﬁed in patients treated with medication or whose serum
DL cholesterol level was ≥140 mg/dl; hypertension was  deﬁned
s systolic blood pressure >140 mmHg  and/or diastolic blood pres-
ure >90 mmHg  and/or the use of anti-hypertensive drugs; diabetes
ellitus was identiﬁed as a glucose blood level >126 mg/dl and/orhe use of anti-diabetic drugs. Medication including antiplatelet
gents, calcium channel blockers, angiotensin-converting enzyme
nhibitors/angiotensin II receptor blockers,  blockers and statins
ere also evaluated.iology 62 (2013) 117–120
In this study, we  deﬁned the success group as the patients who
could maintain sinus rhythm after the administration of bepridil for
more than 6 months and the failure group as those who could not
recover to sinus rhythm after bepridil or could not maintain sinus
rhythm for over 6 months. We  compared the above-mentioned
factors between the two  groups.
The ethics committee at Osaka Rosai Hospital approved this
study, and written informed consent was  obtained from all patients
before the administration of bepridil.
Statistical analysis
All  statistical analyses were performed using SPSS for Win-
dows (SPSS Inc., Chicago, IL, USA). All results were expressed as
means ± SD or number (%). The chi-square test or Fisher exact test
was used to compare frequencies. Quantitative data were analyzed
with the Mann–Whitney U-test. To ﬁnd independent parameters
for successful cardioversion of AF, univariate and multivariate anal-
yses were performed. Variables in the univariate analysis that were
signiﬁcant (p < 0.05) were considered in multivariate models. To
achieve discrimination ability of the independent parameters using
multivariate analysis, a receiving operating characteristics (ROC)
curve was plotted, and the optimal cut-off value for each param-
eter in minimizing the total number of false results and the area
under the curve (AUC) were calculated. Statistical signiﬁcance was
deﬁned as p < 0.05.
Results
Patient characteristics
The  study population consisted of 119 patients with non-
valvular AF (82 men  and 37 women). The mean age of the patients
studied was  62.7 ± 10.1 years. Among the 119 patients with refrac-
tory AF, 68 patients received electrical cardioversion but could not
maintain sinus rhythm. The remaining 51 patients refused electri-
cal cardioversion. Before the prescription of bepridil, pilsicainide
was administered to 91 patients, propafenone to 43 patients, ciben-
zoline to 55 patients, and disopyramide to 65 patients. In addition,
all 119 patients refused ablation therapy for AF. After treatment
with bepridil, 57 patients converted to sinus rhythm; however, 12
patients among these 57 patients could not maintain sinus rhythm
for more than 6 months. In these 12 patients, 7 patients received
electrical cardioversion. Therefore, the success group consisted of
45 patients (38%), and the failure group consisted of the remaining
74 patients. Baseline clinical characteristics are summarized in
Table 1.
Parameters for successful cardioversion using bepridil
As  shown in Table 1, the values of hs-CRP and left atrial dimen-
sion were signiﬁcantly lower and ejection fraction was  signiﬁcantly
higher in the success group than in the failure group, while there
were no signiﬁcant differences in the other serum and echocardiog-
raphic parameters, coronary risk factors, or medications between
the two groups. Therefore, the three signiﬁcant markers—hs-CRP,
ejection fraction, and left atrial dimension—were entered into a
multivariate logistic model to identify independent parameters for
successful cardioversion using bepridil. According to this analysis,
hs-CRP and left atrial dimension were the independent parameters
for successful cardioversion using bepridil (Table 2).
By  constructing a ROC curve for hs-CRP and left atrial dimen-
sion, we identiﬁed an optimal cut-off value of 0.25 mg/dl as the
hs-CRP that minimized false positive and negative results (AUC:
0.64), obtaining a sensitivity and speciﬁcity of 86% and 60%, respec-
tively, and we identiﬁed an optimal cut-off value of 46 mm as the




(n  = 45)
Failure  group
(n  = 74)
p-Value
Age (years) 62.1 ± 10.3 63.7 ± 9.9 0.403
Male  (%) 62.2 73.0 0.229
LDL  cholesterol (mg/dl) 102.8 ± 18.6 112.0 ± 95.3 0.422
HDL  cholesterol (mg/dl) 52.4 ± 18.4 49.3 ± 10.6 0.377
Triglyceride  (mg/dl) 198.6 ± 141.6 154.1 ± 92.9 0.060
Glucose  (mg/dl) 106.9 ± 28.2 106.3 ± 21.4 0.908
Hemoglobin  A1c (%) 5.9 ± 1.1 5.7  ± 0.9 0.138
hs-CRP  (mg/dl) 0.22 ± 0.27 0.36 ± 0.42 0.027
Creatinine  (mg/dl) 0.96 ± 0.19 0.90 ± 0.24 0.115
Echocardiographic parameters
Dd  53.2 ± 10.0 52.5 ± 6.7 0.753
EF  64.8 ± 13.9 63.0 ± 8.3 0.043
Left  atrial dimension 45.9 ± 5.3 48.2  ± 5.6 0.027
Coronary  risk factors
Dyslipidemia (%) 28.9 32.4 0.686
Hypertension  (%) 53.3 44.6 0.576
Diabetes  mellitus (%) 20.0 16.2 0.626
Medications
Antiplatelet  agents (%) 8.9 14.9 0.405
Calcium  antagonists (%) 26.7 40.5 0.166
ACEI/ARB  (%) 53.3 45.9 0.850
  blockers (%) 33.3 21.6 0.197
Statins  (%) 26.7 21.6 0.656
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor block-
ers; hs-CRP, high-sensitive C-reactive protein; Dd, left ventricular end-diastolic
dimension;  EF, left ventricular ejection fraction; HDL, high-density lipoprotein; LDL,
low-density lipoprotein.
Table  2
Independent parameters for successful cardioversion using bepridil.
Odds ratio (95% CI) p-Value
Left atrial dimension (mm) 1.25 (1.05–1.48) 0.029
EF 1.42 (0.84–2.41) 0.090













bF, ejection fraction; hs-CRP, high-sensitive C-reactive protein.
eft atrial dimension that minimized false positive and negative
esults (AUC: 0.70), obtaining a sensitivity and speciﬁcity of 75%
nd 67%, respectively (Fig. 1).
Ninety-two patients (77%) received 100 mg/day of bepridil, 20
atients received 150 mg/day, and the other 7 received 200 mg/day.
uring the follow-up period, torsades de pointes or sudden car-
iac death did not occur. Sinus bradycardia occurred in 5 patients,
nd prolonged QTc (>500 ms)  occurred in 7 patients. Discontinua-
ion of bepridil prevented these patients from suffering subsequent
rrhythmic events.
ig. 1. Receiving operating characteristics (ROC) curve for high-sensitive C-reactive
rotein (hs-CRP), left atrial dimension (LAD), and successful cardioversion using
epridil.iology 62 (2013) 117–120 119
Discussion
In the present study, we found that both left atrial dimension
and hs-CRP levels were associated with successful cardioversion of
refractory AF using bepridil.
Although  control of the ventricular response is an acceptable
treatment in certain subgroups of patients with AF, the restoration
and maintenance of sinus rhythm remains the preferred strat-
egy in many patients [12–15]. Although electrical cardioversion is
the most commonly used method for sinus rhythm restoration in
patients with persistent AF, 20% of patients undergoing electrical
cardioversion do not convert [16], and 50% of patients who do suc-
cessfully cardiovert initially experience AF recurrence within the
ﬁrst month after electrical cardioversion [12,13,17]. Thus, phar-
macological cardioversion and maintenance of sinus rhythm are
needed in many patients. It has been reported that bepridil (a multi-
channel blocker) is effective for maintaining sinus rhythm after
cardioversion, even in patients with failed electrical cardioversion
[9].
Inﬂammation has been implicated in the pathogenesis of sev-
eral cardiovascular diseases, most notably atherosclerosis. There is
now also substantial evidence linking inﬂammation to the initiation
and perpetuation of AF [18]. Cardiac surgery and cardiopulmonary
bypass induce a systemic inﬂammatory response that is mani-
fested as higher levels of hs-CRP that may  contribute to the high
recurrence of postoperative AF [19]. Chung et al. ﬁrst reported an
association between AF and elevated hs-CRP in non-postoperative
AF [20]. Thereafter, the association between hs-CRP and the pres-
ence of AF was supported by many studies [1,21].
In addition to providing insight into the relationship between
inﬂammation and AF, the measurement of hs-CRP might be use-
ful clinically to manage patients with AF. Relapse into AF after
cardioversion is common and represents a challenging therapeu-
tic problem. The measurement of hs-CRP prior to cardioversion
may help in the risk stratiﬁcation of patients at increased risk of
recurrence. Some evidence has suggested that the measurement of
baseline hs-CRP might provide prognostic information regarding
the immediate and long-term success of electrical cardioversion
[1,21–23]. The present study also showed that, in selected patients
with refractory AF, hs-CRP in addition to left atrial dimension can be
a good marker for predicting the effects of bepridil on the mainte-
nance of sinus rhythm. With regard to left atrial dimension, Makita
et al. also reported that left atrium size was  one of the independent
predictors for AF recurrence [24].
Our previous data showed that bepridil, especially low-dose
bepridil (100 mg/day), could maintain sinus rhythm in refractory
AF patients without fatal side effects. Although bepridil is an effec-
tive tool for AF conversion in some refractory cases, the substantial
drug-related adverse effects, including sudden death, raised ques-
tions about using bepridil to treat AF. Because the mortality of AF
patients is low even under a standard rate control strategy, the
balance between the beneﬁts and risks of bepridil should be deter-
mined on an individual basis [25]. This study demonstrated that
hs-CRP in addition to left atrial dimension is useful for identify-
ing individuals with refractory AF who are more likely to maintain
sinus rhythm using bepridil.
Limitations
Except  for hs-CRP levels, we  did not assess the other
inﬂammation markers including the tumor necrosis factor-alpha,
interleukin-6, P-selectin, E-selectin, CD-40 ligand, and vascular
cell adhesion molecule-1. However, although these inﬂammation
markers were useful, they are expensive and less evident as com-
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o predict the effects of bepridil in the patients with refractory AF
n this study.
onclusions
This  study showed that when patients show preserved left atrial
imension and a low grade of inﬂammation, bepridil is effective in
estoring sinus rhythm even for refractory AF, including AF cases in
hich electrical cardioversion has failed.
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